4//SEC Filing
Kaye Edward M. MD 4
Accession 0001522780-25-000009
CIK 0001623526other
Filed
Dec 4, 7:00 PM ET
Accepted
Dec 5, 8:50 PM ET
Size
16.6 KB
Accession
0001522780-25-000009
Insider Transaction Report
Form 4
Kaye Edward M. MD
Director
Transactions
- Exercise/Conversion
Common Stock
2025-12-03+26,250→ 77,555 total - Sale
Common Stock
2025-12-04$30.76/sh−5,222$160,647→ 72,333 total - Sale
Common Stock
2025-12-04$31.32/sh−1,231$38,550→ 71,102 total - Sale
Common Stock
2025-12-05$31.33/sh−6,367$199,481→ 64,735 total - Sale
Common Stock
2025-12-05$31.15/sh−1,681$52,358→ 63,054 total - Sale
Common Stock
2025-12-05$31.85/sh−500$15,923→ 62,554 total - Exercise/Conversion
Performance Stock Units
2025-12-03−26,250→ 0 totalExp: 2025-12-03→ Common Stock (26,250 underlying)
Footnotes (9)
- [F1]The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3, 4, 6, and 7 of this Form 4.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive.
- [F5]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.69 to $31.61 per share, inclusive.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.70 to $31.96 per share, inclusive.
- [F8]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- [F9]Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
Documents
Issuer
Stoke Therapeutics, Inc.
CIK 0001623526
Entity typeother
Related Parties
1- filerCIK 0001522780
Filing Metadata
- Form type
- 4
- Filed
- Dec 4, 7:00 PM ET
- Accepted
- Dec 5, 8:50 PM ET
- Size
- 16.6 KB